Dr Inge Marie Svane

Oncology

Interview at ESMO 2025 with Inge Marie Svane

ESMO25: Immuno-therapies and translational research in oncol...

Dr Inge Marie Svane – Professor in Clinical cancer immune therapy and director of the translational research centre, CCIT, on IO Biotech's ESMO25 data

News

Vogenx surpasses expectations with $81M IPO

With $81.3 million raised, Vogenx is the latest in a staggering summer of biotech IPOs. But the queue past this point looks thin.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks